Merck on Wednesday touted trial wins for a pair of Welireg combos. But the combination win with Merck’s own Keytruda represented more of a definite victory, according to one group of analysts. More: Merck eyes life after Keytruda LOE with
read moreTexas Attorney General Ken Paxton has sued Kenvue, alleging that the Johnson & Johnson consumer health spinoff “deceptively” marketed Tylenol to pregnant mothers despite knowing that early exposure to the drug’s active ingredient, acetaminophen, causes a “significantly increased risk of
read moreAfter weighing other options amid a continued sales struggle, the company will look to take the only approved hemophilia A gene therapy off its plate two years after its launch. More: BioMarin resigned to ending journey with hemophilia A gene
read moreThe FDA has issued another complete response letter to Regeneron over its high-dose Eylea due to unresolved issues at a Novo Nordisk manufacturing plant. The company, however, is making progress in lining up alternate manufacturing help. More: Regeneron reports another
read moreNovartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. But despite its two biggest brands underperforming, the company still delivered 7% groupwide sales growth. More: Newer drugs came to Novartis’ aid as 2
read more
New data support European filing for nonsteroidal topical treatment More: Opzelura shows strong results in phase 3b trial for moderate atopic dermatitis Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals